SNSE
Sensei Biotherapeutics, Inc.
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“After evaluating the conditions described above in the aggregate, the Company has concluded that there is substantial doubt about its ability to continue as a going concern.”View the 10-Q filed May 15, 2026
Company with tickers: SNSE
CIK
1829802
CUSIP
81728A207
Shares Outstanding
1,340,281
Website
https://www.senseibio.com
13F Activity (30d)
4 filings
3 filers
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Josiah Craver | principal accounting officer | Appointed | 2026-06-15 |
| Brian Stephenson | Chief Financial Officer | Appointed | 2026-06-15 |
| Anand Parikh | President and Chief Executive Officer | Appointed | 2026-06-15 |
| Kristian Humer | director | Appointed | 2026-06-10 |
| Bob Holmen | director | Appointed | 2026-06-10 |